Neurizon Therapeutics has reported positive topline results from an open-label extension (OLE) study of its lead candidate ...

ROME, AUG 19 - An Italo-US team of scientists have made a breakthrough in the early diagnosis of amyotrophic lateral ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that causes the gradual loss of motor neurons in the brain and spinal cord, leading to muscle weakness, paralysis, and ...

GetNews Press Release.DelveInsight’s “ Amyotrophic Lateral Sclerosis (ALS) – Pipeline Insight, 2025 ” offers a detailed analysis of the evolving therapeutic landscape for ALS, a fatal ...

The ALS therapy ATH-1105 entered the brain and spinal cord at dose-proportional levels in healthy volunteers, and had a good ...

Yet another biotech is facing a delay from the FDA as the agency reels from intense staffing cuts. | Yet another biotech is ...

By analyzing millions of messenger RNA molecules (mRNA) during the course of ALS, researchers at Stockholm University, in ...

SineuGene gets China NMPA & US FDA nods to initiate phase I/IIa trial of gene therapy, SNUG01 to treat amyotrophic lateral sclerosis: Beijing Monday, August 18, 2025, 18:00 Hrs [I ...

The U.S. Food and Drug Administration has approved the ketamine product, KETARx, for use in surgical pain management.

The onset of motor neurone disease (MND) left Sarah without a voice and the use of her hands at the age of 34. It was within ...

A patient with amyotrophic lateral sclerosis (ALS) has become the first person in the world to control an iPad entirely by ...